LENZ Therapeutics Inc(LENZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:10 PM ET (Korea 10/31 07:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.48 | Insider Own | 13.51% | Shs Outstand | 31.4M | Perf Week | -3.48% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 70.67% | Insider Trans | - | Shs Float | 27.2M | Perf Month | -19.53% |
| Enterprise Value | -0.10B | PEG | - | EPS next Q | -0.72 | Inst Own | 95.06% | Short Float | 33.48% | Perf Quarter | -38.94% |
| Income | -0.14B | P/S | 7.75 | EPS this Y | -41.7% | Inst Trans | -1.4% | Short Ratio | 11.14 | Perf Half Y | -65.65% |
| Sales | 0.01B | P/B | 0.44 | EPS next 5Y | 38.22% | ROA | -66.72% | Short Interest | 9.10M | Perf YTD | -80.94% |
| Book/sh | 6.98 | P/C | 0.49 | EPS past 3/5Y | 39.53% 19.13% | ROE | -72.69% | 52W High | -90.51% ($32.13) | Perf Year | -89.99% |
| Cash/sh | 6.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -63.94% | 52W Low | 1.84% ($2.99) | Perf 3Y | -72.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -112.65% | Gross Margin | 82.86% | Volatility(W/M) | 8.8% 6.96% | Perf 5Y | -94.94% |
| Dividend TTM | - | EV/Sales | -8.16 | Sales Y/Y TTM | -29.38% | Oper. Margin | -1211.17% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.31 | EPS Q/Q | -68.45% | Profit Margin | -1134.97% | RSI (14) | 35.74 | Recom | 1.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.55 | Sales Q/Q | -72.93% | SMA20 | -9.79% ($3.38) | Beta | 0.83 | Target Price | $17.86 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/10/28 | SMA50 | -25.04% ($4.07) | Rel Volume | 2.77 | Prev Close | $3.49 |
| Employees | 152 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -10.84% -19.44% | SMA200 | -61.97% ($8.02) | Avg Volume(3M) | 0.82M | Price | $3.05 |
| IPO | 2021/6/25 | Option/Short | Yes/Yes | Trades | 5887 | Volume | 2,264,278 | Change | -12.61% |
💊 Lens Therapeutics is an ophthalmology-focused pharmaceutical company targeting the treatment of presbyopia (age-related farsightedness). It is an early-stage commercial company that has advanced its aceclidine-based eye drop new drug through to the commercialization stage, obtained approval from the U.S. Food and Drug Administration (FDA), and has begun generating meaningful product revenue.
Over the past 1 year, on the lower side
91% below its 1-year high.
Traded more than usual. That is 277% of its average volume.
LENZ has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -41.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $775. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
33.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #361 of 597 in the industry
Based on market cap of $96M.
KZIA#360 Kazia Therapeutics Limited ADR $97M PER - LENZ#361 LENZ Therapeutics Inc $96M PER - 
NORD#362 Nordicus Partners Corp $96M PER - 
RTSN#363 Retension Pharmaceuticals Inc $95M PER - 
GNLX#364 Genelux Corp $94M PER - 
FAQ
What kind of company is LENZ?
LENZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LENZ?
The market cap of LENZ is approximately $96M, ranking 4,484 within its sector.
What is the 52-week high and low for LENZ?
LENZ has recorded a 52-week high of $32.13 and a low of $2.99.
